News Search Year - Any - 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2009 2008 Archive November 20, 2017 Deciphera Pharmaceuticals Reports Data from Ongoing Phase 1 Clinical Study of DCC-2618 at the 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology Archive November 14, 2017 Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2017 Financial Results and Corporate Highlights Archive November 10, 2017 Deciphera Pharmaceuticals, Inc. Reports Data Analysis from the Ongoing Phase 1 Clinical Trial of DCC-2618 at the Annual Meeting of The Connective Tissue Oncology Society Archive November 6, 2017 Deciphera Pharmaceuticals, Inc. to Report Clinical Data with DCC-2618 at the Upcoming 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology Archive October 3, 2017 Deciphera Pharmaceuticals Announces Closing of Initial Public Offering and Exercise of Option to Purchase Additional Shares Archive September 27, 2017 Deciphera Pharmaceuticals Announces Pricing of Initial Public Offering Archive September 11, 2017 Deciphera Pharmaceuticals Reports Updated Data from Ongoing Phase 1 Clinical Study of DCC-2618 at the European Society of Medical Oncology 2017 Congress Archive September 5, 2017 Deciphera Pharmaceuticals Announces FDA Orphan Drug Designation for DCC-2618 for the Treatment of Glioblastoma Multiforme and Anaplastic Astrocytoma Archive August 31, 2017 Deciphera Pharmaceuticals to Present Updated Data from Ongoing Phase 1 Study of DCC-2618 at the 2017 European Society for Medical Clinical Oncology Annual Congress Archive June 5, 2017 Deciphera Pharmaceuticals Reports Updated Phase 1 Clinical Study Results with DCC-2618 at 2017 American Society of Clinical Oncology Annual Meeting
Archive November 20, 2017 Deciphera Pharmaceuticals Reports Data from Ongoing Phase 1 Clinical Study of DCC-2618 at the 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
Archive November 14, 2017 Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2017 Financial Results and Corporate Highlights
Archive November 10, 2017 Deciphera Pharmaceuticals, Inc. Reports Data Analysis from the Ongoing Phase 1 Clinical Trial of DCC-2618 at the Annual Meeting of The Connective Tissue Oncology Society
Archive November 6, 2017 Deciphera Pharmaceuticals, Inc. to Report Clinical Data with DCC-2618 at the Upcoming 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
Archive October 3, 2017 Deciphera Pharmaceuticals Announces Closing of Initial Public Offering and Exercise of Option to Purchase Additional Shares
Archive September 11, 2017 Deciphera Pharmaceuticals Reports Updated Data from Ongoing Phase 1 Clinical Study of DCC-2618 at the European Society of Medical Oncology 2017 Congress
Archive September 5, 2017 Deciphera Pharmaceuticals Announces FDA Orphan Drug Designation for DCC-2618 for the Treatment of Glioblastoma Multiforme and Anaplastic Astrocytoma
Archive August 31, 2017 Deciphera Pharmaceuticals to Present Updated Data from Ongoing Phase 1 Study of DCC-2618 at the 2017 European Society for Medical Clinical Oncology Annual Congress
Archive June 5, 2017 Deciphera Pharmaceuticals Reports Updated Phase 1 Clinical Study Results with DCC-2618 at 2017 American Society of Clinical Oncology Annual Meeting
